02213nas a2200217 4500000000100000008004100001260001200042100001900054700002300073700001300096700001400109700001700123700001900140700001700159245008700176856006300263300001100326490000800337520163600345022001401981 2015 d c10/20151 aMartins-Melo F1 aAssunção-Ramos A1 aRamos AN1 aAlencar C1 aMontenegro R1 aDe Oliveira ML1 aHeukelbach J00aLeprosy-related mortality in Brazil: a neglected condition of a neglected disease. uhttps://academic.oup.com/trstmh/article/109/10/643/2461519 a643-520 v1093 a

BACKGROUND: Leprosy is a public health problem and a neglected condition of morbidity and mortality in several countries of the world. We analysed time trends and spatiotemporal patterns of leprosy-related mortality in Brazil.

METHODS: We performed a nationwide population-based study using secondary mortality data. We included all deaths that occurred in Brazil between 2000 and 2011, in which leprosy was mentioned in any field of death certificates.

RESULTS: Leprosy was identified in 7732/12 491 280 deaths (0.1%). Average annual age-adjusted mortality rate was 0.43 deaths/100 000 inhabitants (95% CI 0.40-0.46). The burden of leprosy deaths was higher among males, elderly, black race/colour and in leprosy-endemic regions. Lepromatous leprosy was the most common clinical form mentioned. Mortality rates showed a significant nationwide decrease over the period (annual percent change [APC]: -2.8%; 95% CI -4.2 to -2.4). We observed decreasing mortality rates in the South, Southeast and Central-West regions, while the rates remained stable in North and Northeast regions. Spatial and spatiotemporal high-risk clusters for leprosy-related deaths were distributed mainly in highly endemic and socio-economically deprived regions.

CONCLUSIONS: Leprosy is a neglected cause of death in Brazil since the disease is preventable, and a cost-effective treatment is available. Sustainable control measures should include appropriate management and systematic monitoring of leprosy-related complications, such as severe leprosy reactions and adverse effects to multidrug therapy.

 a1878-3503